Global Gastroesophageal Cancer

Global Gastroesophageal Cancer Market Research Report: Forecast (2022-2027)

By Indication (Squamous Cell Carcinoma, Adenocarcinoma), By Diagnosis (Endoscopy, Biopsy, Barium Swallow X-ray, CT/PET Scans, MRI), By Treatment (Esophagectomy, Endoscopic Therapy, Chemotherapy (Carbo Read more

  • Healthcare
  • Jun 2022
  • 192
  • HC22089

Market Definition

Gastric & esophageal cancers are collectively known as gastroesophageal (GE) cancer and are among the leading causes of cancer deaths worldwide. Patients with early-stage GE cancer may experience dyspepsia, anorexia, dysphagia, weight loss, or abdominal pain and are often prescribed a combination of surgery & chemotherapy, with or without radiation.

There are multiple strategies for delivering neoadjuvant & adjuvant chemotherapies; however no existence of any optimal strategy. Surgery remains crucial for esophageal SCC (squamous cell carcinoma), whereas, in metastatic or unresectable diseases, there's a limited impact of traditional SOC (standard-of-care) treatments on patient outcomes.

Market Insights

The Global Gastroesophageal Cancer Market is projected to grow at around 15.8% CAGR during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the growing number of tobacco & alcohol consumers, lifestyle disorders, and the increasing prevalence of gastroesophageal reflux diseases (GERDs) & obesity.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR 15.8%
Regions Covered North America: The US, Canada, Mexico
Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
South America: Brazil, Rest of Latin America
Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled

AstraZeneca PLC, Amgen Inc., Bayer AG, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others

Unit Denominations USD Million/Billion

 

The epidemiology of GE cancer has significantly transformed over several years, especially across developed countries. Since there are no early symptoms, esophageal cancer is diagnosed mainly at advanced stages. It owes prominently to heavy smoking & alcohol usage and growing instances of diseases like gastroesophageal reflux, obesity, & gastric ulcer, among others, which increase the risk of developing gastric cancer.

Even with significant developments in multimodality treatments, the prognosis for GE cancer is still inadequate, with a below 20% 5-year survival rate. However, rapid approvals for the combined use of systemic therapies & new targeted agents as first-line treatments are projected to generate growth opportunities for the Global Gastroesophageal Cancer Market through 2027.

Additionally, the remarkable efficacy of immune checkpoint inhibitors, especially Opdivo & Keytruda, would further augment the market expansion in the nearer future. Various targeted therapies in late-stage development, coupled with easy insurance reimbursements, are also anticipated to boost the market in the years to come.

However, aspects like the high costs of therapies and their adverse effects like mouth sores, loss of appetite, hair loss, diarrhea, etc., which can greatly damage some vital nerves of the body, might hinder the growth of the Global Gastroesophageal Market during 2022-27.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Gastroesophageal Cancer Market Trends & Insights
  4. Global Gastroesophageal Cancer Market Regulation & Policy, By Country
  5. Global Gastroesophageal Cancer Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Gastroesophageal Cancer Market Hotspot and Opportunities
  7. Global Gastroesophageal Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Indication
        1. Squamous Cell Carcinoma
        2. Adenocarcinoma
      2. By Diagnosis
        1. Endoscopy
        2. Biopsy
        3. Barium Swallow X-ray
        4. CT/PET Scans
        5. MRI
      3. By Treatment
        1. Esophagectomy
        2. Endoscopic Therapy
        3. Chemotherapy
          1. Carboplatin
          2. Paclitaxel (Taxol)
          3. Oxaliplatin
          4. Capecitabine
          5. Cisplatin
          6. 5-fluorouracil (5-FU)
          7. Others
        4. Radiation Therapy
          1. External-Beam Radiation Therapy (EBRT)
          2. Internal radiation therapy (Brachytherapy)
        5. Immunotherapy
          1. Keytruda (Pembrolizumab)
          2. Opdivo (Nivolumab)
          3. Yervoy (Ipilimumab)
        6. Targeted Therapy
          1. Trastuzumab
          2. Enhertu (Fam-trastuzumab deruxtecan)
          3. Ramucirumab
          4. Entrectinib
          5. Larotrectinib
      4. By End-User
        1. Hospitals
        2. Clinics
        3. Specialty Cancer Centers
      5. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      6. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Gastroesophageal Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Indication
      2. By Diagnosis
      3. By Treatment
      4. By End-User
      5. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Gastroesophageal Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Indication
      2. By Diagnosis
      3. By Treatment
      4. By End-User
      5. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Gastroesophageal Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Indication
      2. By Diagnosis
      3. By Treatment
      4. By End-User
      5. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Gastroesophageal Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Indication
      2. By Diagnosis
      3. By Treatment
      4. By End-User
      5. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Gastroesophageal Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Indication
      2. By Diagnosis
      3. By Treatment
      4. By End-User
      5. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia-Pacific
  13. Global Gastroesophageal Cancer Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. AstraZeneca PLC
      2. Amgen Inc.
      3. Bayer AG
      4. Bristol Myers Squibb
      5. Boehringer Ingelheim
      6. Eli Lilly and Company
      7. F. Hoffmann-La Roche AG
      8. Gilead Sciences, Inc.
      9. Merck & Co., Inc.
      10. Novartis International AG
      11. Pfizer Inc.
      12. Sanofi S.A.
      13. Others
  15. Disclaimer
Gastroesophageal Cancer Market Segmentation
*This field is required